0.3107  0.023 (8.07%)		09-16 16:00
Open: 0.2901 High: 0.315 Volume: 2,678,186		Pre. Close: 0.2875 Low: 0.285 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0.36	1-year :	0.42
Resists	First :	0.31	Second :	0.36
Pivot price	0.31
Supports	First :	0.29	Second :	0.28
MAs	MA(5) :	0.31	MA(20) :	0.31
	MA(100) :	0.3	MA(250) :	0.36
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	85.6	D(3) :	85.6
RSI	RSI(14): 57.7
52-week	High :	0.83	Low :	0.21

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ TYME ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.32 - 0.32	0.32 - 0.32
Low:	0.28 - 0.28	0.28 - 0.28
Close:	0.31 - 0.31	0.31 - 0.31

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.

Wed, 26 Jul 2023
Tale as old as Tyme: how a successful African digital bank landed in the Philippines - Tech in Asia

Tue, 23 May 2023
South African challenger bank TymeBank raises $77.8M from Norrsken22 and Blue Earth Capital - TechCrunch

Tue, 23 May 2023
Digital banking group Tyme lands $77.8m in pre-Series C funding - FinTech Futures

Mon, 19 Sep 2022
Syros closes $60M merger with Bedminster's TYME - NJBIZ

Fri, 16 Sep 2022
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement - Business Wire

Thu, 15 Sep 2022
Syros and Tyme Technologies Announce Stockholder Approval of Merger - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.14
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.